We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Cellutome System for Treatment of Individual Lesions in EB Pts

This study is currently recruiting participants.
Verified February 2017 by Masonic Cancer Center, University of Minnesota
Sponsor:
ClinicalTrials.gov Identifier:
NCT02670837
First Posted: February 2, 2016
Last Update Posted: February 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota
  Purpose
Few but persistent wounds often remain even after successful hematopoietic cell transplantation for systemic genodermatosis epidermolysis bullosa (EB). The investigators propose local wound therapy using epidermal skin grafting from the same donor that provided the hematopoietic graft, or from the same EB individual with a mosaic (naturally gene corrected) skin. In both cases permissive immune system and skin chimerism is expected to enable long-term epidermal engraftment and wound healing. The investigators will use FDA approved vacuum device (CelluTome®, Regulation number 878.4820) that enables painless, bloodless and scar-free harvesting of epidermis and its transfer on a square of surgical tape (Tegaderm®) to the recipient as a wound dressing.

Condition Intervention
Epidermolysis Bullosa Device: Cellutome Epidermal Harvesting System

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Study of Epidermal Grafting Using the CelluTome Epidermal Harvesting System for the Treatment of Individual Lesions in Persons With Epidermolysis Bullosa [MT2015-36]

Resource links provided by NLM:


Further study details as provided by Masonic Cancer Center, University of Minnesota:

Primary Outcome Measures:
  • Percentage of grafts successfully treated [ Time Frame: 12 weeks after grafting ]

    If the body surface area affected by the wound is at least 50%

    lower at 12 weeks relative to baseline, the graft will be considered

    successful.



Secondary Outcome Measures:
  • Safety of grafted skin [ Time Frame: 1 year after grafting ]
    Percentage of patients who have had a 6 week period of lesion free skin by the time they are 1 year post grafting.

  • Percentage change of a patient's IScoreEB [ Time Frame: 6 weeks after grafting ]
  • Percentage change of a patient's IScoreEB [ Time Frame: 12 weeks after grafting ]
  • Safety of the body sites of the donor [ Time Frame: 1 year after grafting ]
    Percentage of donors with no evidence of non-healed skin


Estimated Enrollment: 40
Actual Study Start Date: August 4, 2016
Estimated Study Completion Date: June 2021
Estimated Primary Completion Date: June 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Graft from HCT donor
Cells are harvested from a donor using Cellutome, then transferred via Tegaderm to the recipient's wound with up to 3 donor harvest sites/treated wound sites on day 0.
Device: Cellutome Epidermal Harvesting System
Experimental: Self donor from intact skin patch
Cells are harvested from the subject using Cellutome, then transferred via Tegaderm to that subject's wound with up to 3 harvest sites/treated wound sites on day 0.
Device: Cellutome Epidermal Harvesting System

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Patient (Recipient)

  • Diagnosis of Dystrophic Epidermolysis Bullosa (DEB) or Junctional Epidermolysis Bullosa (JEB) with two or more areas of blistering each of which are at least 10 cm^2, visibly free from infection and meets the eligibility for Arm A or Arm B based on the skin graft source:
  • Cell harvest from previous hematopoietic cell transplantation donor (Arm A) - not applicable if Arm B

    • At least 1 year after hematopoietic cell transplantation with hematopoietic donor chimerism

      • Minimum acceptable donor chimerism is ≥5% without intervention in the prior 6 months (e.g., manipulation of immune suppressive therapy, use of donor lymphocytes or infusion of hematopoietic stem cells).
    • No history of pre-BMT autoimmune cytopenias
    • Off immune suppressive therapy
    • Original transplant donor is available and willing to be the epidermis donor
  • Self-donation (Arm B) - not applicable if Arm A

    • Proven somatic reversion by clinical exam and immune fluorescence (antigen mapping)
    • Site for skin grafting free of cellulitis and any other clinically evident abnormalities
    • Meets donor eligibility
  • Insurance pre-authorization for procedure
  • Voluntary written consent (patient or parent/guardian for minors with assent) prior to any research related procedures or treatment.

Skin Graft Donor (either hematopoietic cell transplantation donor for the EB patient [Arm A] or EB patient herself/himself [Arm B])

  • Age > 2 years (based on prior safety testing of the device)
  • Healthy on physical examination in the opinion of the evaluating provider
  • Known negativity for Hepatitis B and C, HIV, and HTLV1/2
  • Voluntary written consent (donor or parent/guardian for minors with assent) prior to any research related procedures
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02670837


Contacts
Contact: Kim Nelson, RN 612-273-2925 knelso62@fairview.org

Locations
United States, Minnesota
University of Minnesota Masonic Cancer Center and Medical Center Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Kim Nelson    612-273-2925    knelso62@fairview.org   
Principal Investigator: Jakub Tolar, MD, PhD         
Sponsors and Collaborators
Masonic Cancer Center, University of Minnesota
Investigators
Principal Investigator: Jakub Tolar, MD, PhD Masonic Cancer Center, University of Minnesota
  More Information

Responsible Party: Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier: NCT02670837     History of Changes
Other Study ID Numbers: 2015LS154
First Submitted: January 8, 2016
First Posted: February 2, 2016
Last Update Posted: February 23, 2017
Last Verified: February 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Epidermolysis Bullosa
Skin Abnormalities
Congenital Abnormalities
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Skin Diseases, Vesiculobullous